OPUS GENETICS INC
IRDNASDAQTrading Snapshot
- Day Range
- $3.40 – $3.69
- 52-Week Range
- $1.70 – $7.07
- Volume (shares)
- 1,033,143
- Avg Volume (shares)
- —
- Shares Outstanding
- 83.2M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $755,000
- P/E Ratio
- —
- P/S Ratio
- 31.1x
- EPS (TTM)
- $-1.29
- Dividend Yield
- —
- Dilution (1yr)
- +1870.6%
OPUS GENETICS INC
IRD
StockOtter · stockotter.spaceAbout OPUS GENETICS INC
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
Opus Genetics NASDAQ: IRD outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investo
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood Strategic collab
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by positive results from pivo
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses
Opus Genetics to Present at the Chardan Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rate